Accueil   Diary - News   All news Adocia strengthens its BioChaperone Combo patent porfolio

Adocia strengthens its BioChaperone Combo patent porfolio

Adocia (Euronext Paris: FR0011184241 – ADOC) announced that the two major patent families covering BioChaperone Combo were granted in two of the main potential markets for this product. BioChaperone Combo is a unique combination, enabled by proprietary BioChaperone technology, of the basal insulin glargine and the prandial insulin lispro. BioChaperone Combo has been successfully tested in 3 different clinical studies in subjects with type 1 and type 2 diabetes and is one of Adocia’s lead clinical development programs.


Read the press release


By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree